Canadian Pantyhose Maker Furloughs 40% of Staff on Trade-War Woes
The threat of US tariffs has caused a Montreal-based women's clothing maker to place more than a third of its workers on leave.
SRTX is putting 40% of its 350 employees and contractors on temporary layoff, Chief Executive Officer Katherine Homuth said in a statement. The company has 85% of its sales in the US and has invested 'tens of millions' in Canadian factories, she said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Biovica Signs Agreement with Fifth Tier-1 US Biopharma Company
UPPSALA, SE / / June 11, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) - along with an initial Work Order of ~800 kSEK - with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology drug development, becomes the fifth Tier-1 US biopharma company to join Biovica's Pharma Services customer base. The agreement covers testing of Phase 1 clinical trial samples in support of the development of next-generation CDK4/6 inhibitors and is a pilot study with DiviTum® TKa. " This marks a milestone in our growing customer base, highlighting the increasing relevance of Biovica's TKa biomarker assay in advanced cancer therapy development. It demonstrates the strong and growing recognition of the value our assay brings to the development of next-generation oncology treatments that ultimately benefit cancer patients. ," said Anders Rylander, CEO of Biovica. Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments Biovica signs agreement with fifth Tier-1 US biopharma company SOURCE: Biovica International View the original press release on ACCESS Newswire Sign in to access your portfolio
Business Insider
36 minutes ago
- Business Insider
Qantas is pulling the plug on Jetstar Asia — and 500 jobs
Qantas is shutting down Jetstar Asia, its Singapore-based budget carrier, blaming rising operating costs and a crowded market. The budget airline will cease operations on July 31 after more than two decades. Jetstar Asia will continue flights until then on a "progressively reduced schedule," Qantas said in a statement on Wednesday. "Despite delivering exceptional customer service and operational reliability, Jetstar Asia has been impacted by rising supplier costs, high airport fees, and intensified competition in the region," the Australian company said. Jetstar Asia flies 16 routes from Singapore to destinations in Malaysia, Thailand, Indonesia, Japan, the Philippines, China, Sri Lanka, and Australia. Jetstar operations in Australia, New Zealand and Japan will not be affected. Customers booked on canceled flights will be offered full refunds, and Qantas will try to move them to other airlines where possible. The shutdown will also result in the loss of more than 500 jobs, a Jetstar Asia spokesperson told Business Insider. Affected employees will be given redundancy benefits and assistance with other roles within Qantas and other airlines. Qantas added that 13 Jetstar Asia Airbus A320 aircraft will be progressively redirected to Australia and New Zealand. Qantas did not immediately respond to a request for comment. Competition among budget carriers in Southeast Asia was "brutal," Alan Tan, a professor specializing in aviation law at the National University of Singapore's Law School, told Business Insider. "The departure is a great loss from the viewpoint of price and service competition for travellers," he said. Virgin Australia IPO The closure comes on the same day that Virgin Australia announced its intention to list on the stock market in Sydney on June 24. The shares will be priced at A$2.90, raising A$685 million and valuing the company at A$2.3 billion. The IPO will allow some existing investors, including Bain Capital, Qatar Airways Group, and the Virgin Group, to realize part of their holdings. Investors participating in the offer are expected to hold about 30% of shares on issue, with the remainder being held by existing investors. Virgin carries about 20 million passengers a year on more than 100 aircraft. It operates 76 routes to 38 destinations across its domestic and short-haul international airline business. From next week it will start long-haul international services between Australia and Doha in partnership with Qatar Airways, which has a 25% stake in Virgin. Budget model is 'dead' United Airlines CEO Scott Kirby earlier this month criticized the budget airline model and called it "crappy." He told the "Future of Everything" event that the low-cost carrier model was "dead." "The model was screw the customer," he said. "It was like trick people, get them to buy, and get them to come, and then charge them a whole bunch of fees that they aren't expecting … disclosures buried in legalese," he continued. "Their problem is they got big enough that they needed repeat customers. They don't get them." His comments came the same day that United announced a new partnership with JetBlue, which some consider to be a budget carrier.
CNBC
40 minutes ago
- CNBC
Europe's fastest-growing nuclear fusion company raises $148 million in record funding round
German start-up Proxima Fusion on Wednesday announced it had raised 130 million euros ($148 million) in a record funding round, with investors hopeful the company can soon develop the world's first commercial nuclear fusion power plant. The Series A financing round, which was co-led by investors Cherry Ventures and Balderton Capital, represents the largest private fusion investment round in Europe to date. The buzz around nuclear fusion has kicked into overdrive in recent years. Advocates say the technology, which is the process that powers the sun and stars, can play a pivotal role in the energy transition. Fusion energy is the process of jamming together two hydrogen atoms to form one helium atom, which releases massive amounts of power. Scientists and engineers have been scrambling to recreate and harness nuclear fusion since the theory was first understood in the 1930s. "Fusion has become a real, strategic opportunity to shift global energy dependence from natural resources to technological leadership," Proxima Fusion CEO and co-founder Francesco Sciortino said in a statement. "Proxima is perfectly positioned to harness that momentum by uniting a spectacular engineering and manufacturing team with world-leading research institutions, accelerating the path toward bringing the first European fusion power plant online in the next decade," he added. If nuclear fusion can be replicated at an industrial scale, the International Atomic Energy Agency (IAEA) says the technology could provide virtually limitless clean, safe and affordable energy that meets the world's demand. Not everyone is convinced, however. Researchers have suggested the technology is likely still a long way off from being ready to be scaled up for commercial use. The Series A financing round brings Proxima Fusion's total funding to more than 185 million euros in private and public capital, accelerating the Munich-based firm's mission of building the first stellarator-based fusion power plant in the 2030s. An alternative to the more common tokamak, a stellarator is a device that uses magnetic fields to confine plasma in the shape of a donut, according to the U.S. Department of Energy. These magnetic fields allow scientists to control the plasma particles and allow the right conditions for nuclear fusion. "Stellarators aren't just the most technologically viable approach to fusion energy—they're the power plants of the future, capable of leading Europe into a new era of clean energy," Daniel Waterhouse, partner at Balderton Capital, said in a statement. Proxima Fusion was founded two years ago as a spin out from the Max Planck Institute for Plasma Physics (IPP).
